JP2002515020A - TNF−α転換酵素 - Google Patents
TNF−α転換酵素Info
- Publication number
- JP2002515020A JP2002515020A JP50310797A JP50310797A JP2002515020A JP 2002515020 A JP2002515020 A JP 2002515020A JP 50310797 A JP50310797 A JP 50310797A JP 50310797 A JP50310797 A JP 50310797A JP 2002515020 A JP2002515020 A JP 2002515020A
- Authority
- JP
- Japan
- Prior art keywords
- tace
- polypeptide
- tnf
- isolated
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6489—Metalloendopeptidases (3.4.24)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- AIDS & HIV (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Microbiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.単離され精製されたTACEポリペプチド。 2.約80kDの分子量を有する、請求項1に記載の単離され精製されたポリ ペプチド。 3.非グリコシル型である、請求項1に記載の単離され精製されたポリペプチ ド。 4.配列番号2のアミノ酸18−Xaa、ここにおいてXaaは、アミノ酸6 71ないし824からなるグループから選択されるアミノ酸である、を含むポリ ペプチドからなるグループから選択される、請求項1に記載の単離され精製され たポリペプチド。 5.請求項1に記載のポリペプチドに結合する単離され精製された抗体。 6.抗体がモノクローナル抗体である、請求項5に記載された単離され精製さ れた抗体。 7.分子のTACE抑制活性を検出する方法であって、当該分子を基質と混合 し、請求項1に記載のポリペプチドを混合物とインキュベートし、そして基質切 断の量をクロマトグラフィーによって決定する、ことを含む前記方法。 8.基質が、アミノ酸配列Leu−Ala−Gln−Ala−Val−Arg −Ser−Serを含む、請求項7に記載の分子のTACE抑制活性を検出する 方法。 9.請求項1に記載のポリペプチドを、当該ポリペプチドの抑制分子の構造に 基づく設計に用いる方法であって、当該ポリペプチドの三次元構造を決定し、基 質の可能性のある結合部位についての三次元構造を分析し、予測される反応部位 を取り込んだ分子を合成し、そして分子のポリペプチド−抑制活性を測定する、 工程を含む前記方法。 10.分子のTNF−切断活性を検出する方法であって、前記分子を、アミノ酸 配列Leu−Ala−Gln−Ala−Val−Arg−Ser−Serを含む 基質とインキュベートし、そして基質切断の量を測定する事を含む、前記方法。 11.以下のもの: (a)天然TACE遺伝子のコード領域; (b)配列番号1のヌクレオチド52−2472を含むcDNA (c)(a )または(b)の核酸と少なくも80%同一であり、そしてTNF−αを26k D型から17kD型へ転換するポリペプチドをコードする核酸;および (d)(a)、(b)または(c)に定義された核酸と遺伝子コードの結果縮 重しており、かつ、生物学的に活性なTACEをコードする核酸 からなるグループから選択される、単離された核酸。 12.TACEがヒトTACEである、請求項11に記載の単離された核酸。 13.配列番号2のアミノ酸18−671を含むポリペプチドをコードする、請 求項11に記載の単離された核酸。 14.請求項11に記載の核酸配列を発現するための発現ベクター。 15.請求項11に記載の発現ベクターで感染または形質転換された宿主細胞。 16.発現を促進する条件下で請求項15に記載の宿主細胞を培養し、そして培 養培地からポリペプチドを回収することを含む、TACEポリペプチドの製造方 法。 17.哺乳類の細胞膜からのTNF−αの切断を抑制する方法であって、配列番 号2のアミノ酸18−671の配列を含む酵素のTNF−αタンパク質分解活性 を抑制する化合物の有効量を当該哺乳類に投与することを含む、前記方法。 18.TNF−αの配列番号2のアミノ酸18−671の配列を有する酵素との 結合を阻止することを含む、細胞膜からのTNF−α切断を抑制する方法。 19.TNF−αの過剰発現または非制御発現によって特徴付けられる疾患を有 する哺乳類の治療方法であって、配列番号2のアミノ酸18−671の配列を含 む酵素のTNF−αタンパク質分解活性を有効に抑制する化合物の量を含む組成 物を当該哺乳類に投与することを含む、前記方法。
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US48245895A | 1995-06-08 | 1995-06-08 | |
US08/428,458 | 1995-06-08 | ||
US50461495A | 1995-07-20 | 1995-07-20 | |
US08/504,614 | 1995-07-20 | ||
US08/655,345 | 1996-05-23 | ||
US08/655,345 US5830742A (en) | 1995-06-08 | 1996-05-23 | TNF-α converting enzyme |
PCT/US1996/008407 WO1996041624A1 (en) | 1995-06-08 | 1996-06-03 | TNF-α CONVERTING ENZYME |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2002515020A true JP2002515020A (ja) | 2002-05-21 |
JP2002515020A5 JP2002515020A5 (ja) | 2004-07-29 |
JP4326022B2 JP4326022B2 (ja) | 2009-09-02 |
Family
ID=27413615
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50310797A Expired - Fee Related JP4326022B2 (ja) | 1995-06-08 | 1996-06-03 | TNF−α転換酵素 |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP0830130B9 (ja) |
JP (1) | JP4326022B2 (ja) |
AT (1) | ATE274346T1 (ja) |
AU (1) | AU712759C (ja) |
CA (1) | CA2222650C (ja) |
DE (1) | DE69633231T2 (ja) |
DK (1) | DK0830130T3 (ja) |
ES (1) | ES2227598T3 (ja) |
IL (1) | IL122305A0 (ja) |
NO (1) | NO323623B1 (ja) |
NZ (2) | NZ510390A (ja) |
PT (1) | PT830130E (ja) |
WO (1) | WO1996041624A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006518352A (ja) * | 2003-02-21 | 2006-08-10 | マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ | Egfレセプターシグナル伝達の調節のためのtaceまたはアンフィレグリンの阻害 |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6180403B1 (en) | 1999-10-28 | 2001-01-30 | Isis Pharmaceuticals Inc. | Antisense inhibition of tumor necrosis factor alpha converting enzyme (TACE) expression |
US6255064B1 (en) | 1996-03-01 | 2001-07-03 | The Procter & Gamble Company | Disintegrin metalloprotease and its use |
AU2291397A (en) * | 1996-03-26 | 1997-10-17 | Glaxo Group Limited | Tumor necrosis factor alpha convertase |
AU3514997A (en) * | 1996-07-12 | 1998-02-09 | Schering Corporation | Mammalian tnf-alpha convertases |
US5853977A (en) | 1996-07-12 | 1998-12-29 | Schering Corporation | Mammalian TNF-α convertases |
US6046031A (en) * | 1997-01-21 | 2000-04-04 | Human Genome Sciences, Inc. | Metalloproteinases |
AU6181798A (en) * | 1997-02-25 | 1998-09-09 | Case Western Reserve University | Use of a novel disintegrin metalloprotease, mutants, fragments and the ike |
US6551857B2 (en) | 1997-04-04 | 2003-04-22 | Elm Technology Corporation | Three dimensional structure integrated circuits |
US6548633B1 (en) | 1998-12-22 | 2003-04-15 | Genset, S.A. | Complementary DNA's encoding proteins with signal peptides |
US6842704B2 (en) | 1998-02-04 | 2005-01-11 | Immunex Corporation | Crystalline TNF-α-converting enzyme and uses thereof |
JP2004503202A (ja) * | 1998-02-04 | 2004-02-05 | イミュネックス コーポレイション | 結晶性TNF−α変換酵素およびその使用 |
US6632667B1 (en) | 1999-10-28 | 2003-10-14 | Isis Pharmaceuticals, Inc. | Modulation of L-selectin shedding via inhibition of tumor necrosis factor-α converting enzyme (TACE) |
WO2005030798A2 (en) * | 2003-09-24 | 2005-04-07 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | TNFαCONVERTING ENZYME INHIBITORY AGENTS AND STIMULATORY AGENTS- |
ES2755386T5 (es) * | 2006-08-28 | 2023-04-05 | Ares Trading Sa | Proceso para la purificación de proteínas que contienen fragmentos Fc |
ZA200900836B (en) * | 2006-08-28 | 2010-05-26 | Ares Trading Sa | Process for the purification of FC-fusion proteins |
US9150659B2 (en) | 2011-02-01 | 2015-10-06 | Gillian Murphy | Anti-tace antibody molecules and their uses |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05501351A (ja) * | 1989-08-16 | 1993-03-18 | カイロン コーポレイション | プロホルモンタンパク質に対する開裂部位阻止抗体及びその使用 |
JP2930713B2 (ja) * | 1989-08-16 | 1999-08-03 | カイロン コーポレイション | タンパク質ホルモン形成の抑制用の組成物およびその使用法 |
DE59106996D1 (de) * | 1990-06-22 | 1996-01-11 | Jens Luedemann | Dna-sequenz für eine serin-protease und damit zusammenhängende gegenstände. |
EP0592423B1 (en) * | 1990-08-06 | 2000-11-15 | Chiron Corporation | Methods for the identification of cytokine convertase inhibitors |
EP0648225A1 (en) * | 1992-06-25 | 1995-04-19 | Chiron Corporation | Compositions for the inhibition of protein hormone formation and uses thereof |
WO1995024501A1 (en) * | 1994-03-07 | 1995-09-14 | Cetus Oncology Corporation | Compositions for the inhibition of tnf formation and uses thereof |
AU2291397A (en) * | 1996-03-26 | 1997-10-17 | Glaxo Group Limited | Tumor necrosis factor alpha convertase |
-
1996
- 1996-06-03 ES ES96923209T patent/ES2227598T3/es not_active Expired - Lifetime
- 1996-06-03 EP EP96923209A patent/EP0830130B9/en not_active Expired - Lifetime
- 1996-06-03 NZ NZ510390A patent/NZ510390A/xx not_active IP Right Cessation
- 1996-06-03 DE DE69633231T patent/DE69633231T2/de not_active Expired - Fee Related
- 1996-06-03 AU AU63781/96A patent/AU712759C/en not_active Ceased
- 1996-06-03 WO PCT/US1996/008407 patent/WO1996041624A1/en active IP Right Grant
- 1996-06-03 CA CA002222650A patent/CA2222650C/en not_active Expired - Fee Related
- 1996-06-03 IL IL12230596A patent/IL122305A0/xx not_active IP Right Cessation
- 1996-06-03 NZ NZ312285A patent/NZ312285A/en not_active IP Right Cessation
- 1996-06-03 DK DK96923209T patent/DK0830130T3/da active
- 1996-06-03 PT PT96923209T patent/PT830130E/pt unknown
- 1996-06-03 JP JP50310797A patent/JP4326022B2/ja not_active Expired - Fee Related
- 1996-06-03 AT AT96923209T patent/ATE274346T1/de not_active IP Right Cessation
-
1997
- 1997-11-26 NO NO19975438A patent/NO323623B1/no not_active IP Right Cessation
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006518352A (ja) * | 2003-02-21 | 2006-08-10 | マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ | Egfレセプターシグナル伝達の調節のためのtaceまたはアンフィレグリンの阻害 |
JP4723474B2 (ja) * | 2003-02-21 | 2011-07-13 | マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ | Egfレセプターシグナル伝達の調節のためのtaceまたはアンフィレグリンの阻害 |
JP2011148798A (ja) * | 2003-02-21 | 2011-08-04 | Max-Planck-Ges Zur Foerderung Der Wissenschaften Ev | Egfレセプターシグナル伝達の調節のためのtaceまたはアンフィレグリンの阻害 |
Also Published As
Publication number | Publication date |
---|---|
DE69633231T2 (de) | 2005-08-04 |
DE69633231D1 (de) | 2004-09-30 |
EP0830130A4 (en) | 2000-03-29 |
EP0830130B9 (en) | 2004-12-29 |
CA2222650C (en) | 2009-10-13 |
MX9709744A (es) | 1998-07-31 |
ES2227598T3 (es) | 2005-04-01 |
EP0830130B1 (en) | 2004-08-25 |
CA2222650A1 (en) | 1996-12-27 |
AU712759C (en) | 2001-08-09 |
NZ510390A (en) | 2002-11-26 |
AU6378196A (en) | 1997-01-09 |
AU712759B2 (en) | 1999-11-18 |
NZ312285A (en) | 2001-04-27 |
JP4326022B2 (ja) | 2009-09-02 |
PT830130E (pt) | 2004-11-30 |
WO1996041624A1 (en) | 1996-12-27 |
IL122305A0 (en) | 1998-04-05 |
NO975438L (no) | 1998-02-06 |
NO323623B1 (no) | 2007-06-18 |
ATE274346T1 (de) | 2004-09-15 |
NO975438D0 (no) | 1997-11-26 |
EP0830130A1 (en) | 1998-03-25 |
DK0830130T3 (da) | 2004-12-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7695948B2 (en) | Antibodies that bind TNF-α converting enzyme | |
US5830742A (en) | TNF-α converting enzyme | |
JP2002515020A (ja) | TNF−α転換酵素 | |
CA2296766C (en) | Aggrecan degrading metallo proteases | |
JP2000507943A (ja) | 腫瘍壊死因子αコンバーターゼ | |
JP2003502006A (ja) | Il−17rhdna及びポリペプチド | |
JP2000050885A (ja) | カテプシンに対する抗体およびそれらの利用 | |
JP2002524048A (ja) | キナーゼ機能を有するポリペプチドをコードするヒトcDNA | |
JP2002500011A (ja) | V201dna及びポリペプチド | |
JP2000512147A (ja) | IL―1/TNF―α活性化キナーゼ(ITAK)、並びに当該キナーゼを作成しそして使用する方法 | |
US6670135B1 (en) | Semaphorin polypeptides | |
JP2002508969A (ja) | 精巣特異的ヒトsvph1−8プロテイナーゼ | |
AU752369B2 (en) | TNF-alpha converting enzyme | |
AU745623B2 (en) | V196 DNA and polypeptides | |
JP2002524046A (ja) | キナーゼ作用を有するポリペプチドをコードするマウスdna分子 | |
JP2001521742A (ja) | Svph1−26dnaおよびポリペプチド | |
JP2000157263A (ja) | 新規なヒトカテプシンyタンパク質及びそれをコードす る遺伝子並びにそれらの利用 | |
MXPA97009744A (en) | Enzima convertidora tnf-a | |
JP2002500012A (ja) | V197dna及びポリペプチド | |
WO2000041537A2 (en) | Use of desert hedgehog protein |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060328 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20060627 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20060814 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070724 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20071024 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20071203 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071126 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20080902 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081201 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20090205 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090525 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090609 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120619 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |